Global Genotyping Industry

Global Genotyping Industry

  • October 2019 •
  • 112 pages •
  • Report ID: 5798664 •
  • Format: PDF
Genotyping market worldwide is projected to grow by US$31 Billion, driven by a compounded growth of 20.6%. Polymerase Chain Reaction (PCR), one of the segments analyzed and sized in this study, displays the potential to grow at over 20.4%. The shifting dynamics supporting this growth makes it critical for businesses in this space to keep abreast of the changing pulse of the market. Poised to reach over US$14.8 Billion by the year 2025, Polymerase Chain Reaction (PCR) will bring in healthy gains adding significant momentum to global growth.

- Representing the developed world, the United States will maintain a 23.2% growth momentum. Within Europe, which continues to remain an important element in the world economy, Germany will add over US$1 Billion to the region’s size and clout in the next 5 to 6 years. Over US$1.4 Billion worth of projected demand in the region will come from Rest of Europe markets. In Japan, Polymerase Chain Reaction (PCR) will reach a market size of US$1.2 Billion by the close of the analysis period. As the world’s second largest economy and the new game changer in global markets, China exhibits the potential to grow at 19.8% over the next couple of years and add approximately US$5.2 Billion in terms of addressable opportunity for the picking by aspiring businesses and their astute leaders. Presented in visually rich graphics are these and many more need-to-know quantitative data important in ensuring quality of strategy decisions, be it entry into new markets or allocation of resources within a portfolio. Several macroeconomic factors and internal market forces will shape growth and development of demand patterns in emerging countries in Asia-Pacific. All research viewpoints presented are based on validated engagements from influencers in the market, whose opinions supersede all other research methodologies.

- Competitors identified in this market include, among others, Affymetrix, Inc.; Agilent Technologies, Inc.; Beckman Coulter, Inc.; Fluidigm Corporation; GE Healthcare; Illumina, Inc.; Life Technologies Corporation; Qiagen NV; Roche Diagnostics; Sequenom, Inc.